Pfizer Study MEETS Endpoint and 3 Dow Movers Not to Miss
JPMorgan Chase & Co. (NYSE:JPM) has found, following an internal inquiry into the recent trading losses, that one of its executives talked London trader Bruno Iksil into raising valuations on some bets that were losing money, according to the Wall Street Journal.
The Coca-Cola Company (NYSE:KO) might have Fraser & Neave’s food and beverage division in mind, while the latter ponders whether to take Heineken’s (HINKY.PK) offer for Asia Pacific Breweries, according to the Wall Street Journal.
Microsoft Corporation (NASDAQ:MSFT): Economic factors are triggering unseasonably large price decreases for a large number of electronic parts, which provides a near-term buying opportunity for purchasers, says IHS iSuppli. Prices for widely used components including capacitors, crystals, filters, magnetics, oscillators and printed circuit boards all are set to fall at above-average rates in the third and fourth quarters.
Pfizer Inc. (NYSE:PFE) reports that a Phase 4 evaluation that assessed the efficacy and safety of Toviaz, or fesoterodine fumarate, in patients suffering from overactive bladder, or OAB, has met its primary endpoint. Toviaz decreased urge urinary incontinence, or UUI, in patients with OAB who had a suboptimal response to Detrol LA, or tolterodine tartrate extended release, which is a routinely-prescribed treatment for the condition.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.